Advisory Committee Meeting Materials:
January 28, 2014
On January 28, 2014, the committee will meet in open session to discuss and make recommendations on the safety and efficacy of RAGWITEK, a short ragweed pollen allergen extract tablet for sublingual use, manufactured by Merck, indicated for immunotherapy for diagnosed ragweed pollen induced allergic rhinitis, with or without conjunctivitis.
- Announcement- Amendment
This amendment reflects a change in the conference room designation for the meeting.
- Briefing Document- Sponsor (PDF - 2.3MB)
Persons with disabilities having problems accessing the PDF may call 301-827-0314 for assistance.
- Briefing Document- FDA (PDF - 186KB)
- Draft Agenda
- Summary Minutes
- Transcript (PDF - 208KB)
- Waivers for Conflicts of Interest